Table 2 Clinical and demographic characteristics in the all-treated target population
Telavancin | Standard therapy | Overall | |
|---|---|---|---|
(n = 15) | (n = 16) | (n = 31) | |
Age in years (mean ± SD) | 59 ± 16.3 | 60 ± 20.4 | 60 ± 18.2 |
Age ≥65 | 5 (33%) | 7 (44%) | 12 (39%) |
Gender, male | 10 (67%) | 8 (50%) | 18 (58%) |
Race, white | 11 (73%) | 10 (63%) | 21 (68%) |
Body mass index ≥30 | 6 (40%) | 3 (19%) | 9 (29%) |
Diabetes | 7 (47%) | 10 (63%) | 17 (55%) |
Prior antimicrobial therapya | 14 (93%) | 16 (100%) | 30 (97%) |
Vancomycin | 13 (87%) | 14 (88%) | 27 (87%) |
Primary source of bacteremia identified | 12 (80%) | 13 (81%) | 25 (81%) |
IV catheter | 8 (53%) | 9 (56%) | 17 (55%) |
Skin and soft tissue | 3 (20%) | 3 (19%) | 6 (19%) |
Other | 1 (7%) | 1 (6%) | 2 (6%) |
MRSA | 7 (47%) | 8 (50%) | 15 (48%) |